Latest Conference Articles

March 7th 2020, 10:00pm

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

“A person becomes a survivor from the point they are diagnosed and for the balance of their lives,” Dr. Don S. Dizon said in a presentation at the 37th Annual Miami Breast Cancer Conference®.

March 7th 2020, 8:00pm

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

At the 37th Annual Miami Breast Cancer Conference, Dr. Kevin S. Hughes discussed genetic testing and what health care providers should be doing to identify more individuals at risk for cancer.

March 7th 2020, 1:06am

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

Xentuzumab in combination with Verzenio, with or without endocrine therapy, may be safe and effective in treating patients with solid tumors and advanced breast cancer.

March 6th 2020, 11:00pm

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

Premenopausal women with HR-positive, HER2-negative advanced breast cancer experienced improved survival and quality of life with the addition of Kisqali to Zoladex and endocrine therapy to their treatment regimen.

March 6th 2020, 7:13pm

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

Women who had contralateral prophylactic mastectomy reported similar breast satisfaction and quality of life, cancer-related distress and anxiety and depression scores, compared with those who did not undergo the procedure.

February 11th 2020, 1:30pm

DONNA Foundation Marathon Weekend

February 11th 2020, 1:30pm

DONNA Foundation Marathon Weekend

February 11th 2020, 1:30pm

DONNA Foundation Marathon Weekend

January 3rd 2020, 3:00am

Educated Patient® Multiple Myeloma Summit

A multiple myeloma expert helps newly diagnosed patients understand the standard of care for their disease.

December 25th 2019, 2:00am

Educated Patient® Multiple Myeloma Summit

Patients with multiple myeloma have a lot to look forward to in the treatment space thanks to precision medicine, but one treatment option alone will not cure the disease.

December 24th 2019, 12:00am

American Society of Hematology Annual Meeting

New findings show that a wider study is needed for MDM2 inhibitors in treating patients with AML.

December 21st 2019, 3:00am

Educated Patient® Multiple Myeloma Summit

At the 2019 CURE® Educated Patient® Summit on Multiple Myeloma patient advocate and 10-year survivor Terry White had the chance to share advice on handling a cancer diagnosis.

December 20th 2019, 3:00am

Educated Patient® Multiple Myeloma Summit

Naturally, newly diagnosed patients with multiple myeloma have a lot of questions for their physicians. Dr. Joshua Richter had the time to discuss some of them.

December 20th 2019, 12:00am

American Society of Hematology Annual Meeting

Real-world data shows that CAR-T therapy can lower costs for patients with pre-existing comorbidities outside of the clinical setting.

December 18th 2019, 6:57pm

SABCS

Patients with metastatic breast cancer who received an oral version of the chemotherapy drug experienced improved response rates and reductions in peripheral neuropathy compared to those who took the drug intravenously.

December 18th 2019, 3:00am

SABCS

At the 2019 San Antonio Breast Cancer Symposium, Khevin Barnes advocated on behalf of men with breast cancer, but also advocated for more men with breast cancer to join him.

December 18th 2019, 1:00am

SABCS

Patients with early-stage triple-negative breast cancer who did not have circulating tumor DNA in their blood experienced superior outcomes to chemotherapy followed by surgery.

December 16th 2019, 7:17pm

SABCS

Residual cancer burden can help physicians pinpoint accurate long-term predictions about the likelihood that a patient’s breast cancer will return.

December 16th 2019, 12:52am

Educated Patient® Multiple Myeloma Summit

At CURE’s Educated Patient Summit on Multiple Myeloma Dr. Shebli Atrash had the chance to further discuss with CURE what questions he addresses most when patients with multiple myeloma undergo diagnostic testing.

December 15th 2019, 9:57pm

Educated Patient® Multiple Myeloma Summit

At CURE’s Educated Patient Summit on Multiple Myeloma, Dr. Barry Paul discussed the role of minimal residual disease measurement and how it may be used in the future to determine treatment options for patients with myeloma.

December 15th 2019, 2:11am

Educated Patient® Multiple Myeloma Summit

Dr. Cesar Rodriguez offers a message of hope and self-determination for patients with multiple myeloma.

December 14th 2019, 12:00am

SABCS

Women who took estrogen alone as hormone therapy for their menopause experienced decreased rates of breast cancer and death from the disease even after they stopped taking the therapy, when compared to women who took estrogen with progestin.

December 13th 2019, 10:00pm

SABCS

Survival and recurrence rates were similar among patients with breast cancer who either received accelerated partial breast irradiation or whole breast irradiation.

December 13th 2019, 9:00pm

SABCS

This massive event for women with breast cancer just may be “man’s breast friend”.

December 13th 2019, 3:00am

SABCS

Women treated with Arimidex for five years were 50% less likely to have developed breast cancer recurrence compared with women given placebo at nearly 11 years follow-up after stopping treatment.

December 13th 2019, 12:41am

SABCS

Adding Tecentriq to chemotherapy before surgery did not improve the rate of pathologic complete response in patients with advanced, early-stage triple-negative breast cancer.

December 12th 2019, 10:31pm

SABCS

Nearly 65% of patients whose disease had spread to lymph nodes showed no signs of cancer following a regimen of Keytruda plus chemotherapy compared with those who received chemotherapy alone.

December 12th 2019, 1:21am

SABCS

Results from a phase 3 trial showed significant increases in five-year invasive disease-free survival estimates among Japanese patients with hormone receptor-positive, HER2-negative breast cancer.

December 12th 2019, 12:24am

SABCS

Researchers found that the addition of Perjeta to Herceptin plus chemotherapy reduced the relative risk for breast cancer recurrence or death in patients with operable HER2-positive early breast cancer, according to a six-year follow-up.

December 11th 2019, 10:05pm

SABCS

The HER2-targeted antibody-drug conjugate T-DXd achieved a response in 60.9% of patients, according to phase 2 study findings.